This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

HPV

  1. The World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization concluded that a single dose of human papillomavirus (HPV) vaccine delivers solid protection against HPV. Based on the available evidence, SAGE advised that countries may now choose between a one- or two-dose schedule for 9–14-year-old girls and women aged 15 to 20. This is a major step toward reaching the WHO’s global strategy to accelerate the elimination of cervical cancer.The following resource provides background on HPV and cervical cancer, HPV vaccines, and the current evidence and potential impact for a single-dose regimen.
    Published: April 2022
    Type: Resource Page
  2. New evidence shows single-dose HPV vaccination is highly effective
    Published: April 2022
    Type: Article
  3. This is a simple, Excel-based tool for assessing and comparing costs of human papillomavirus (HPV) vaccination programs annually and for a period of 10 years with HPV vaccine products available in the global market. It aims to help country-level policymakers compare products and estimate vaccination program costs for different HPV vaccines, exploring multiple vaccine options at a time. The tool can be used by decision-makers, implementers, technical partners, and others in any country, whether or not the country is eligible for co-funding from Gavi, the Vaccine Alliance. Estimates of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery) are calculated separately, based on user inputs, for two perspectives: (1) the country perspective and (2) the combined country and Gavi perspective (only relevant for Gavi-eligible countries). The tool also calculates the estimated vaccine dose and cold chain volume requirements, which can support operational planning and logistics.It is important to note that cost is only one consideration when selecting an HPV vaccine product, and users involved in decision-making around new vaccine introduction or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages below. For questions or support, contact PATH's Health Economics & Outcomes Research team: HEOR@path.org.
    Published: March 2022
    Type: Resource Page
  4. Global national HPV vaccine introduction maps.
    Published: March 2022
    Type: Resource Page
  5. This important milestone will provide countries with an additional option for HPV vaccination at an affordable price and will contribute to sustainable supply of HPV vaccine—allowing more girls to be reached with HPV vaccines.
    Published: October 2021
    Type: Announcement
  6. To better understand the success factors and barriers to introducing the HPV vaccine at a national scale, PATH, in collaboration with the World Health Organization (WHO), undertook a cross sectional descriptive study of secondary data from HPV post-introduction evaluation (PIE) reports from a mix of 17 LMICs. Using a standardized form, planning and implementation data were extracted for 18 programmatic areas documented in countries’ PIE reports.The results of this report are presented below in an interactive dashboard, presentation, and fact sheet.Updated May 2022 to add Interactive Dashboard.
    Published: September 2021
    Type: Resource Page
  7. A brief on the current program, challenges with uptake, the potential impact of a reduced schedule, and the process from policy to implementation.
    Published: September 2021
    Type: Resource Page
  8. Together with over 400 external stakeholders from across 50 countries, PATH has crafted a new institutional strategy that responds to the current crises we face as a global community, to the needs and priorities of our local partners, and to the resounding calls for the continued transformation of our sector. To bring our new strategy to life for our external partners, we’ve developed a strategy brochure. The brochure explains why PATH exists (our mission), what we will do (our priorities) and, perhaps most importantly, how we will do it (our change strategies).
    Published: June 2021
    Type: Resource Page
  9. Microarray patch (MAP) technologies can address the need for improved presentations of vaccines and pharmaceuticals. The PATH Center of Excellence for MAP Technology is working to advance MAP development for high priority needs in low- and middle-income countries (LMICs). A key element of this work is evaluating global health use cases and understanding potential usability, acceptability, and programmatic fit of MAPs for specific applications and use cases, including rabies, HPV, and outbreak response.This report describes the user and program needs activities that have been conducted as part of the MAP Center of Excellence and includes a high-level summary of the results for different applications and lessons learned that are relevant for the MAP platform as a whole.
    Published: April 2021
    Type: Resource Page
  10. The Single-Dose HPV Vaccine Evaluation Consortium encompasses eight leading independent research institutions working together to collate and synthesize existing evidence and evaluate new data on the potential for single-dose HPV vaccination.
    Published: January 2021
    Type: Resource Page
Load more